CXCR2 and chronic obstructive pulmonary disease: Similarly, the CXCR2 inhibitor Danirixin (GlaxoSmithKline) has been tested in phase 2 clinical trials in patients with COPD and influenza, where it reduced neutrophilia (Madan et al., 2019; Roberts et al., 2019).